Curative Biotechnology Inc (CUBT) Balance Sheet
CUBT balance sheet, 2025
December 31, 2025 · U.S. dollars$2.1M assets = $8.2M liabilities + −$6.1M equity
Liabilities exceed assets: shareholders’ equity is negative (−$6.1M).
Both columns are drawn to the same scale: what CUBT owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CUBT financial health
Descriptive bands, not a rating. Fiscal 2025.
CUBT balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $65,9092016 | $2.1M2025 | +47.0%/yr | |
| Total liabilities | $702,2932016 | $8.2M2025 | +31.4%/yr | |
| Shareholders’ equity | −$636,3842016 | −$6.1M2025 | — | |
| Cash & short-term investments | $02017 | $45,0432025 | — | |
| Total debt | $198,4672016 | $1.4M2025 | +23.8%/yr | |
| Net cash (debt) | −$198,4672016 | −$1.3M2025 | −$1.1M | |
| Working capital | −$692,0622016 | −$8.1M2025 | −$7.4M | |
| Book value per share | −$0.302016 | −$0.812024 | — | |
| Current ratio | 0.012016 | 0.012025 | 0.00 | |
| Shares outstanding | 2.2M2016 | 6.1M2024 | +13.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CUBT assets
CUBT liabilities and equity
CUBT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CUBT balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $45,043 | $19,534 | $56,400 | $58,668 | $670,263 | $160,607 | $0 | $0 | $0 | — |
| Cash & equivalents | $45,043 | $19,534 | $56,400 | $58,668 | $670,263 | $160,607 | $0 | $0 | $0 | — |
| Receivables | $0 | $0 | $115,625 | $0 | $25,000 | $70,000 | $0 | $0 | $8,581 | $8,581 |
| Inventory | $0 | $0 | −$115,625 | $0 | $0 | $0 | $0 | $0 | $0 | $1,650 |
| Other current assets | $64,992 | $192,354 | $548,051 | $10,000 | $58,642 | $1.9M | $0 | $0 | $0 | $0 |
| Total current assets | $110,035 | $211,888 | $604,451 | $68,668 | $753,905 | $2.1M | $0 | $0 | $8,581 | $10,231 |
| Property, plant & equipment (net) | $1,025 | $2,392 | $5,809 | $6,264 | $6,720 | $2,338 | $2,867 | $3,396 | $3,925 | $4,454 |
| Goodwill & intangible assets | $1.3M | $1.3M | $1.4M | $1.6M | $1.6M | $140,299 | $36,908 | $0 | $8,581 | $8,581 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $690,971 | $600,563 | $570,563 | $390,104 | $92,976 | $1 | $0 | $41,680 | $37,871 | $42,643 |
| Total assets | $2.1M | $2.2M | $2.6M | $2.1M | $2.4M | $2.3M | $39,775 | $45,076 | $58,958 | $65,909 |
| Liabilities | ||||||||||
| Accounts payable | — | $4.1M | $3.5M | $3.4M | $726,904 | $97,830 | $397,103 | $535,590 | $519,707 | $503,826 |
| Short-term debt | $1.4M | $1.4M | $2.3M | $1.1M | — | $559,761 | $125 | $198,767 | $198,617 | $198,467 |
| Deferred revenue | — | — | −$3.5M | −$3.4M | — | −$98 | — | −$535,590 | −$519,707 | −$503,826 |
| Total current liabilities | $8.2M | $7.1M | $5.7M | $4.6M | $730,335 | $664,991 | $397,103 | $734,357 | $718,325 | $702,293 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $18.1M | $18.0M | $6.1M | $0 | $0 | $0 | $0 |
| Total liabilities | $8.2M | $7.1M | $5.7M | $22.6M | $18.8M | $6.8M | $397,103 | $734,357 | $718,325 | $702,293 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $715 | $91,926 | $90,326 | $57,927 | $57,065 | $83 | $322,800 | $322,800 | $322,800 | $322,800 |
| Retained earnings (deficit) | −$44.8M | −$41.9M | −$38.2M | −$32.4M | −$26.9M | −$8.1M | −$3.7M | −$4.0M | −$4.0M | −$4.0M |
| Accumulated other comprehensive income | — | — | $0 | — | $0 | — | — | — | — | — |
| Total shareholders' equity | −$6.1M | −$4.9M | −$3.1M | −$2.5M | $1.7M | −$4.5M | −$357,328 | −$689,281 | −$659,367 | −$636,384 |
| Key figures | ||||||||||
| Total debt | $1.4M | $1.4M | $2.3M | $1.1M | — | $559,761 | $125 | $198,767 | $198,617 | $198,467 |
| Net cash (debt) | −$1.3M | −$1.3M | −$2.2M | −$1.0M | — | −$399,154 | −$125 | −$198,767 | −$198,617 | −$198,467 |
| Working capital | −$8.1M | −$6.9M | −$5.1M | −$4.5M | $23,570 | $1.5M | −$397,103 | −$734,357 | −$709,744 | −$692,062 |
| Tangible book value | −$7.4M | −$6.3M | −$4.6M | −$4.2M | $123,266 | −$4.7M | −$394,236 | −$689,281 | −$667,948 | −$644,965 |
| Book value per share | — | −$0.81 | −$0.71 | −$0.67 | $0.78 | — | −$0.17 | −$0.32 | −$0.31 | −$0.30 |
| Shares outstanding | — | 6.1M | 4.4M | 3.8M | 2.2M | — | 2.2M | 2.2M | 2.2M | 2.2M |
| Current ratio | 0.01 | 0.03 | 0.11 | 0.01 | 1.03 | 3.21 | 0.00 | 0.00 | 0.01 | 0.01 |
| Quick ratio | 0.01 | 0.00 | 0.03 | 0.01 | 0.95 | 0.35 | 0.00 | 0.00 | 0.01 | 0.01 |
| Equity / assets | −288.6% | −227.1% | −120.7% | −121.5% | 69.7% | −198.8% | −898.4% | −1,529.2% | −1,118.4% | −965.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $145,258 | $44,801 | $45,043 | $30,740 | $26,905 | $218,263 | $19,534 | $36,840 | $304,351 | $118,603 | $56,400 | $35,583 |
| Cash & equivalents | $145,258 | $44,801 | $45,043 | $30,740 | $26,905 | $218,263 | $19,534 | $36,840 | $304,351 | $118,603 | $56,400 | $35,583 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $10,000 | $0 | $115,625 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $57,018 | $47,257 | $64,992 | $92,380 | $53,230 | $137,361 | $192,354 | $281,011 | $118,293 | $205,077 | $432,426 | $117,213 |
| Total current assets | $202,276 | $92,058 | $110,035 | $123,120 | $80,135 | $355,624 | $211,888 | $317,851 | $432,644 | $323,680 | $604,451 | $152,796 |
| Property, plant & equipment (net) | $342 | $683 | $1,025 | $1,367 | $1,708 | $2,050 | $2,392 | $2,734 | $3,076 | $3,417 | $5,809 | $5,923 |
| Goodwill & intangible assets | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.4M | $1.4M | $1.4M | $1.4M | $1.6M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $690,971 | $690,971 | $690,971 | $690,971 | $690,971 | $600,564 | $600,563 | $600,564 | $600,564 | $654,358 | $570,563 | $415,556 |
| Total assets | $2.2M | $2.1M | $2.1M | $2.1M | $2.1M | $2.3M | $2.2M | $2.3M | $2.4M | $2.4M | $2.6M | $2.2M |
| Liabilities | ||||||||||||
| Accounts payable | — | — | — | — | — | $4.2M | $4.1M | — | — | — | $3.5M | — |
| Short-term debt | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $3.1M | $1.4M | $2.8M | $2.5M | $2.2M | $2.3M | $1.4M |
| Total current liabilities | $8.5M | $8.4M | $8.2M | $8.0M | $7.5M | $7.3M | $7.1M | $6.8M | $6.2M | $5.9M | $5.7M | $6.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $8.5M | $8.4M | $8.2M | $8.0M | $7.5M | $7.3M | $7.1M | $6.8M | $6.2M | $5.9M | $5.7M | $6.1M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $889 | $766 | $715 | $107,276 | $101,276 | $101,110 | $91,926 | $90,326 | $90,326 | $90,326 | $90,326 | $62,892 |
| Retained earnings (deficit) | −$46.7M | −$45.4M | −$44.8M | −$44.5M | −$43.5M | −$42.9M | −$41.9M | −$40.9M | −$40.0M | −$39.1M | −$38.2M | −$35.1M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | −$90,326 | −$90,325 | −$90,325 | −$62,892 |
| Total shareholders' equity | −$6.4M | −$6.3M | −$6.1M | −$5.9M | −$5.3M | −$5.0M | −$4.9M | −$4.5M | −$3.8M | −$3.5M | −$3.1M | −$3.9M |
| Key figures | ||||||||||||
| Total debt | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $3.1M | $1.4M | $2.8M | $2.5M | $2.2M | $2.3M | $1.4M |
| Net cash (debt) | −$1.2M | −$1.3M | −$1.3M | −$1.3M | −$1.4M | −$2.9M | −$1.3M | −$2.8M | −$2.2M | −$2.1M | −$2.2M | −$1.4M |
| Working capital | −$8.3M | −$8.3M | −$8.1M | −$7.9M | −$7.4M | −$6.9M | −$6.9M | −$6.5M | −$5.8M | −$5.6M | −$5.1M | −$6.0M |
| Tangible book value | −$7.7M | −$7.6M | −$7.4M | −$7.2M | −$6.7M | −$6.3M | −$6.3M | −$5.9M | −$5.2M | −$4.9M | −$4.6M | −$5.5M |
| Book value per share | −$0.77 | −$0.86 | −$0.85 | −$0.88 | −$0.79 | — | — | — | — | — | — | — |
| Shares outstanding | 8.3M | 7.4M | 7.2M | 6.7M | 6.8M | — | — | — | — | — | — | — |
| Current ratio | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | 0.05 | 0.03 | 0.05 | 0.07 | 0.05 | 0.11 | 0.02 |
| Quick ratio | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.05 | 0.02 | 0.03 | 0.01 |
| Equity / assets | −296.1% | −304.6% | −288.6% | −274.0% | −251.6% | −218.5% | −227.1% | −196.0% | −155.1% | −146.6% | −120.7% | −177.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
CUBT financial position
At the end of fiscal 2025 (December 31, 2025), Curative Biotechnology had total assets of $2.1 million (down 2.5% from a year earlier), total liabilities of $8.2 million and shareholders' equity of -$6.1 million. It held $0.0 million in cash and short-term investments against $1.4 million of debt, net debt of $1.3 million. Its current ratio was 0.01. In the latest quarter (ended June 30, 2026) total assets were $2.2 million and equity -$6.4 million.
Related: CUBT income statement, CUBT cash flow statement, CUBT key metrics. See the CUBT stock overview for the latest quote and news.
CUBT balance sheet FAQ
What are Curative Biotechnology's total assets?
Curative Biotechnology reported total assets of $2.1 million at the end of fiscal 2025 (December 31, 2025), compared with $2.2 million a year earlier.
How much debt does Curative Biotechnology have?
Curative Biotechnology had $1.4 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was —.
How much cash does Curative Biotechnology have?
Curative Biotechnology held $0.0 million in cash and short-term investments at the end of fiscal 2025; with $1.4 million of debt that is net debt of $1.3 million.
What is Curative Biotechnology's book value?
Curative Biotechnology's shareholders' equity (book value) was -$6.1 million at the end of fiscal 2025.
What is Curative Biotechnology's current ratio?
Curative Biotechnology had current assets of $0.1 million and current liabilities of $8.2 million, a current ratio of 0.01 (current liabilities exceed current assets).
How much goodwill does Curative Biotechnology have?
Curative Biotechnology carried $1.3 million of goodwill and intangible assets, 62.0% of total assets, at the end of fiscal 2025.